Navigation Links
Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinson's Therapeutic Development in 2010
Date:9/15/2009

NEW YORK, Sept. 15 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $12 million in 2010 funding for prioritized research toward transformative treatments and a cure for Parkinson's disease.

Funding is open to academic and industry researchers through the Foundation's Pipeline Programs, which consist of three annually recurring initiatives, known collectively as The Edmond J. Safra Core Programs for PD Research, as well as the industry-exclusive Therapeutics Development Initiative. The Foundation seeks investigator-initiated proposals focused on the following critical points along the translational pathway to new therapies for Parkinson's disease:

  • Testing Novel Hypotheses: Quick support for high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD.
  • Validating Novel Targets: Support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model -- an essential step to the development of potential targeted therapies.
  • Catalyzing and Expanding Preclinical Development: Industry-exclusive support for preclinical development of Parkinson's disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
  • Clinically Testing Novel Therapies: Support for clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD.

"The Pipeline Programs reflect our Foundation's portfolio approach to supporting the most promising work across multiple stages of development," said Katie Hood, the Foundation's CEO. "The programs are complementary expressions of our mission to prioritize and aggressively drive research that can significantly improve patients' quality of life -- sooner rather than later."

Brief program descriptions follow. Full details are available at www.michaeljfox.org/research.

Rapid Response Innovation Awards, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

No deadline; applications accepted at any time

Rapid Response Innovation Awards provide up to $75,000 for projects with little to no existing preliminary data, but with potential to significantly impact understanding or treatment of Parkinson's disease. MJFF is eager to fund high-risk, high-reward projects tackling critical scientific roadblocks to open new avenues for PD therapy development. Research proposals may be submitted at any time and funding decisions are made within six weeks of receiving the application.

Target Validation, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million (in two funding rounds)

Deadlines: ROUND 1: 6 p.m. ET, Tuesday, December 15, 2009;

ROUND 2: 6 p.m. ET, Tuesday, June 1, 2010

Funding anticipated: ROUND 1: June 2010

ROUND 2: December 2010

Target Validation provides awards of up to $250,000 to validate the therapeutic potential of scientific discoveries and push them one step closer to the clinic. While research continues to identify new genetic, cellular and biological targets for therapeutic intervention to benefit PD patients, the translation of these discoveries into practical treatments requires additional applied work. Target Validation funds this work with the ultimate goal of 'de-risking' potential investment in the most promising targets by biotech and pharmaceutical companies, who are generally best-suited to carry promising therapies forward into the clinic.

Therapeutics Development Initiative

Total available funding: $5 million, exclusively to industry

Deadline: 6 p.m. ET, Monday, January 18, 2010; Spring 2010 deadline TBA

Funding Anticipated: June 2010

The Therapeutics Development Initiative (TDI) seeks to stimulate preclinical Parkinson's disease research projects of up to two years duration at for-profit institutions. There is no pre-set budget limitation for applications under this initiative. The program prioritizes key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.

Clinical Intervention Awards, An Edmond J. Safra Core Program for PD Research Total available funding: $3 million

Deadline: 6 p.m. ET, Tuesday, December 15, 2009

Funding anticipated: July 2010

The Clinical Intervention Awards drive clinical intervention trials of promising therapeutic approaches with potential to significantly improve the treatment of PD. Ideal proposals will focus on tests of novel treatments that can slow or halt disease progression, or that can greatly reduce PD motor and non-motor symptoms beyond (and without the complications of) current standards of care. There is no pre-set budget limitation for applications under this initiative.

Applications for all programs must be submitted through www.michaeljfox.org.

Pre-proposals (required for all programs except Rapid Response Innovation Awards) will be reviewed by the Foundation's scientific staff and a panel of scientific experts. Applicants whose pre-proposals meet the review criteria will be invited to submit full proposals. Conference calls with MJFF Research Programs staff to further clarify the aims and goals of the Pipeline Programs will be held in advance of the application deadline. Date and time details for each conference call are available at www.michaeljfox.org.

Additional research funds for the coming year will be announced at later dates under the Foundation's 2010 Critical Challenges initiatives -- programs that provide funding for top MJFF research priorities and areas of particular emphasis.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. The Foundation has funded $149 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision ... executive staff with the addition of industry sales leader, Thomas (Tom) Slott, as ... the national distribution and sales network, direct the efforts of the surgical sales ...
Breaking Medicine News(10 mins):